Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Share-based Compensation (2020 - 2025)

Bolt Biotherapeutics' Share-based Compensation history spans 6 years, with the latest figure at $407000.0 for Q3 2025.

  • For Q3 2025, Share-based Compensation fell 62.93% year-over-year to $407000.0; the TTM value through Sep 2025 reached $2.9 million, down 64.75%, while the annual FY2024 figure was $7.4 million, 19.69% down from the prior year.
  • Share-based Compensation for Q3 2025 was $407000.0 at Bolt Biotherapeutics, down from $625000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.9 million in Q1 2022 and bottomed at $407000.0 in Q3 2025.
  • The 5-year median for Share-based Compensation is $2.1 million (2021), against an average of $1.9 million.
  • The largest annual shift saw Share-based Compensation soared 837.33% in 2021 before it tumbled 77.88% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $2.1 million in 2021, then dropped by 0.89% to $2.1 million in 2022, then fell by 2.59% to $2.1 million in 2023, then tumbled by 42.84% to $1.2 million in 2024, then tumbled by 65.57% to $407000.0 in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Share-based Compensation are $407000.0 (Q3 2025), $625000.0 (Q2 2025), and $709000.0 (Q1 2025).